Sorafenib-Induced Interstitial Pneumonitis in a Patient with Hepatocellular Carcinoma: A Case Report
Gut and Liver
; : 543-546, 2010.
Article
em En
| WPRIM
| ID: wpr-37190
Biblioteca responsável:
WPRO
ABSTRACT
Sorafenib is an oral multikinase inhibitor that has shown a survival benefit in patients with advanced hepatocellular carcinoma, and is considered to be generally safe. We treated a patient with interstitial lung disease that was associated with sorafenib therapy for the treatment of advanced hepatocellular carcinoma. A 74-year-old man with hepatitis-C-virus-related hepatocellular carcinoma was treated with sorafenib. After 8 days of sorafenib administration, he received radiation therapy for an intrahepatic tumor located in segment eight. On the 24th day of sorafenib treatment, the patient developed acute interstitial pneumonitis that rapidly improved after the discontinuation of sorafenib and treatment with high-dose steroids. This case alerts physicians to the possibility of sorafenib-induced interstitial lung disease.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Compostos de Fenilureia
/
Esteroides
/
Niacinamida
/
Doenças Pulmonares Intersticiais
/
Carcinoma Hepatocelular
Limite:
Aged
/
Humans
Idioma:
En
Revista:
Gut and Liver
Ano de publicação:
2010
Tipo de documento:
Article